MedTrace Logo

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

NCT04571515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2022-08-08

Study results available
· View outcomes & findings →

Summary

MR-107A-01 is being studied to investigate its efficacy, safety, and dose-response after dental surgery.

Conditions

  • Pain
  • Postoperative Pain
  • Pain, Acute

Interventions

DRUG

MR-107A-01

Oral tablet

DRUG

Placebo

Oral tablet

Sponsors & Collaborators

  • Mylan Inc.

    lead INDUSTRY

Principal Investigators

  • Susanne Vogt · MEDA Pharma GmbH & Co. KG (A Viatris Company)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2020-12-15
Completion
2020-12-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04571515 on ClinicalTrials.gov